7万中国人群持续葡萄糖监测数据特征蓝皮书_40页_1mb

Diabetes Monitoring Report Summary

The report analyzes the use of Continuous Glucose Monitoring (CGM) in diabetes management in China, based on data from 202,566 adults wearing CGM devices. Key findings include:

Introduction

• Diabetes patient population is large, with ~141 million Chinese adults affected (IDF 2021). CGM is emerging as a crucial tool for glucose management, recognized in updated guidelines, alongside SMBG, to improve control and reduce complications.

Chapter 1: Industry Insights—Disease Management Enters a New Phase

• Diabetes management advances with CGM technology, offering real-time, precise glucose data. CGM adoption grows due to guidelines' emphasis on personalization, benefiting individuals with better self-management and economic capacity.
• Non-proliferating trends highlight CGM's role in addressing poor glucose control, but barriers like high costs prevent wider use, emphasizing patient education and cost reduction.

Chapter 2: China CGM Data for Diabetic Patients

• Data from 71,566 users wearing a "Silicon-based动感CGM" show high glucose control: median TIR of 72.3% for type 1 and 86.8% for type 2. Men and type 1 patients are key users, with older ages dominating.
• Low TIR+TBR composite rates indicate persistent hypoglycemia risks needing professional guidance.
• Longer disease duration worsens control, suggesting early CGM use benefits prevention.

Chapter 3: China CGM Data for Non-Diabetic Populations

• Non-diabetic groups show excellent glucose control with median TIR of 97.0% and high self-monitoring awareness.

Chapter 4: CGM Digital Management Implications

• Insights highlight male and type 1 patients as primary users, reinforcing the need for education and cost strategies to expand CGM access.
• Benefits include improved glucose management and reduced complications, with industry-wide implications for healthcare professionals, patients, payers, and policymakers.

Key Conclusions

• CGM use correlates with better glucose control but risks low blood sugar. Filling gaps in non-diabetic and pregnancy-related data, CGM holds transformative potential for diabetes management in China.

Disclaimer

This summary is based on the report's core data and analysis.